Baqsimi™ (glucagon) nasal powder


This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.

BAQSIMI™ (glucagon) nasal powder: Immunogenicity

There is a potential for immunogenicity with Baqsimi (glucagon nasal powder) as with all therapeutic peptides.

Detailed Information

As with all therapeutic peptides, there is the potential for immunogenicity with Baqsimi.1

The detection of antibody formation is highly dependent on the sensitivity and specificity of the assay. Additionally, the observed incidence of antibody, including neutralizing antibody, positivity in an assay may be influenced by several factors including

  • assay methodology

  • sample handling

  • timing of sample collection

  • concomitant medications, and

  • underlying disease.1

For these reasons, comparison of incidence of antibodies to Baqsimi with the incidences of antibodies to other products may be misleading.1

In 3 clinical trials, 3/124 (2%) of participants treated with Baqsimi had treatment-emergent anti-drug antibodies as detected by an affinity capture elution ligand-binding immunogenicity assay. No neutralizing antibodies were detected.1

Enclosed Prescribing Information

BAQSIMI™ (glucagon) nasal powder, for intranasal use, Lilly


1. Baqsimi [package insert]. Indianapolis, IN: Eli Lilly and Company; 2019.


Baqsimi = Baqsimi™ (glucagon) nasal powder

Date of Last Review: July 24, 2019

Contact Lilly

Call Us

If you need information about a Lilly product or want to report an Adverse Event or Product Complaint, you may call us.

Available Mon - Fri, 9am - 7pm EST

Or you can

Chat with us

Chat with us

Submit a Request

Visit Us @LillyMedical